BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 16782928)

  • 1. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.
    George RE; Li S; Medeiros-Nancarrow C; Neuberg D; Marcus K; Shamberger RC; Pulsipher M; Grupp SA; Diller L
    J Clin Oncol; 2006 Jun; 24(18):2891-6. PubMed ID: 16782928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aggressive surgical therapy and radiotherapy for patients with high-risk neuroblastoma treated with rapid sequence tandem transplant.
    von Allmen D; Grupp S; Diller L; Marcus K; Ecklund K; Meyer J; Shamberger RC
    J Pediatr Surg; 2005 Jun; 40(6):936-41; discussion 941. PubMed ID: 15991174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Long-term effect of high dose chemotherapy combined with stem cell transplantation on stage IV neuroblastoma in children].
    Tang SQ; Huang DS; Wang JW; Feng C; Yang G
    Zhongguo Dang Dai Er Ke Za Zhi; 2006 Apr; 8(2):93-6. PubMed ID: 16613697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma.
    Bradfield SM; Douglas JG; Hawkins DS; Sanders JE; Park JR
    Cancer; 2004 Mar; 100(6):1268-75. PubMed ID: 15022296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose busulfan and melphalan as conditioning regimen for autologous peripheral blood progenitor cell transplantation in high-risk neuroblastoma patients.
    Molina B; Alonso L; Gonzalez-Vicent M; Andion M; Hernandez C; Lassaletta A; Cormenzana M; Lopez-Ibor B; Villa M; Molina J; Diaz MA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):115-23. PubMed ID: 21299340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue.
    Cohn SL; Moss TJ; Hoover M; Katzenstein HM; Haut PR; Morgan ER; Green AA; Kletzel M
    Bone Marrow Transplant; 1997 Oct; 20(7):543-51. PubMed ID: 9337055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation in patients with poor-prognosis solid tumors - Bulgarian experience.
    Avramova B; Jordanova M; Michailov G; Konstantinov D; Christosova I; Bobev D
    J BUON; 2006; 11(4):433-8. PubMed ID: 17309174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.
    Hoppe BS; Moskowitz CH; Filippa DA; Moskowitz CS; Kewalramani T; Zelenetz AD; Yahalom J
    J Clin Oncol; 2008 Apr; 26(11):1858-64. PubMed ID: 18332466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome for children <4 years of age with malignant central nervous system tumors treated with high-dose chemotherapy and autologous stem cell rescue.
    Thorarinsdottir HK; Rood B; Kamani N; Lafond D; Perez-Albuerne E; Loechelt B; Packer RJ; MacDonald TJ
    Pediatr Blood Cancer; 2007 Mar; 48(3):278-84. PubMed ID: 16456857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tandem high-dose chemotherapy and autologous stem cell rescue in patients over 1 year of age with stage 4 neuroblastoma.
    Sung KW; Lee SH; Yoo KH; Jung HL; Cho EJ; Koo HH; Lee SK; Kim J; Lim DH; Suh YL; Kim DW
    Bone Marrow Transplant; 2007 Jul; 40(1):37-45. PubMed ID: 17468771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
    Wadehra N; Farag S; Bolwell B; Elder P; Penza S; Kalaycio M; Avalos B; Pohlman B; Marcucci G; Sobecks R; Lin T; Andrèsen S; Copelan E
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1343-9. PubMed ID: 17162217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse in the skull after myeloablative therapy for high-risk neuroblastoma.
    Sangthawan D; DesRosiers PM; Randall ME; Robertson K; Goebel S; Fallon R
    Pediatr Hematol Oncol; 2003; 20(1):23-30. PubMed ID: 12687750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel intensive induction therapy for high-risk neuroblastoma utilizing sequential peripheral blood stem cell collection and infusion as hematopoietic support.
    Pradhan KR; Johnson CS; Vik TA; Sender LS; Kreissman SG
    Pediatr Blood Cancer; 2006 Jun; 46(7):793-802. PubMed ID: 16206215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma?
    Al-Faris N; Al Harbi T; Goia C; Pappo A; Doyle J; Gassas A
    Pediatr Blood Cancer; 2007 Aug; 49(2):190-5. PubMed ID: 17262797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcoma.
    Lashkari A; Chow WA; Valdes F; Leong L; Phan V; Twardowski P; Kapoor N; Molina A; Al-Kadhimi Z; Frankel P; Somlo G
    Anticancer Res; 2009 Aug; 29(8):3281-8. PubMed ID: 19661346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isolation and transplantation of highly purified autologous peripheral CD34(+) progenitor cells: purging efficacy, hematopoietic reconstitution and long-term outcome in children with high-risk neuroblastoma.
    Handgretinger R; Lang P; Ihm K; Schumm M; Geiselhart A; Koscielniak E; Hero B; Klingebiel T; Niethammer D
    Bone Marrow Transplant; 2002 May; 29(9):731-6. PubMed ID: 12040469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thiotepa and melphalan based single, tandem, and triple high dose therapy and autologous stem cell transplantation for high risk neuroblastoma.
    Saarinen-Pihkala UM; Hovi L; Koivusalo A; Jahnukainen K; Karikoski R; Sariola H; Wikström S
    Pediatr Blood Cancer; 2012 Dec; 59(7):1190-7. PubMed ID: 22492714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapsed Wilms' tumor with high-dose therapy and autologous hematopoietic stem-cell rescue: the experience at Children's Memorial Hospital.
    Campbell AD; Cohn SL; Reynolds M; Seshadri R; Morgan E; Geissler G; Rademaker A; Marymount M; Kalapurakal J; Haut PR; Duerst R; Kletzel M
    J Clin Oncol; 2004 Jul; 22(14):2885-90. PubMed ID: 15254057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term adverse effects on dentition in children with poor-risk neuroblastoma treated with high-dose chemotherapy and autologous stem cell transplantation with or without total body irradiation.
    Hölttä P; Alaluusua S; Saarinen-Pihkala UM; Wolf J; Nyström M; Hovi L
    Bone Marrow Transplant; 2002 Jan; 29(2):121-7. PubMed ID: 11850706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.